Molecular mechanisms that regulate epidermal growth factor receptor inactivation

Clinical Medicine: Oncology

Volumn 2, Issue , 2008, Pages 47-61

  Ceresa, Brian P ^a   Vanlandingham, Phillip A ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Degradation; EGFR; Endocytosis; MVB

Indexed keywords

EID: 79955938234     PISSN: None     EISSN: 11779314     Source Type: Journal    
DOI: 10.4137/cmo.s498     Document Type: Article

References (112)

1. Agazie, Y.M. and Hayman, M.J. 2003. The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3. Oncogene., 22:6909-18.
2. Andersen, J.N., Jansen, P.G., Echwald, S.M., Mortensen, O.H., Fukada, T., Del Vecchio, R., Tonks, N.K. and Moller, N.P. 2004. A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage. FASEB. J., 18:8-30.
3. Astsaturov, I., Cohen, R.B. and Harari, P.M. 2006. EGFR.-targeting monoclonal antibodies in head and neck cancer. Curr. Cancer Drug Targets, 6:691-710.
4. Babst, M. 2005. A protein's final ESCRT. Traffic, 6:2-9.
5. Babst, M., Odorizzi, G., Estepa, E.J. and Emr, S.D. 2000. Mammalian tumor susceptibility gene 101 (TSG101) and the yeast homologue, Vps23p, function in late endosomal trafficking. Traffic, 1:248-58.
6. Bache, K.G., Brech, A., Mehlum, A. and Stenmark, H. 2003. Hrs regulates multivesicular body formation via ESCRT recruitment to endosomes. J. Cell. Biol., 162:435-42.
7. Bache, K.G., Slagsvold, T., Cabezas, A., Rosendal, K.R., Raiborg, C. and Stenmark, H. 2006a. The Growth-Regulatory Protein HCRP1/ hVps37A Is a Subunit of Mammalian ESCRT-1 and mediates Receptor Down-Regulation. Mol. Biol. Cell., 15:4337-46.
8. Bache, K.G., Stuffers, S., Malerod, L., Slagsvold, T., Raiborg, C., Lechardeur, D., Walchli, S., Luckacs, G.L., Brech, A. and Stenmark, H. 2006b. The ESCRT-III Subunit hVps24 Is Required for Degradation but Not Silencing of the Epidermal Growth Factor Receptor. Mol. Biol. Cell., 17:2513-23.
9. Barford, D., Jia, Z. and Tonks, N.K. 1995. Protein tyrosine phosphatases take off. Nat. Struct. Biol., 2:1043-53.
10. Baulida, J., Kraus, M. H, Alimandi, M., DiFiore, P.P. and Carpenter, G. 1996. All ErbB. Receptors other than the epidermal growth factor receptor are endocytosis impaired. J. Biol. Chem., 271:5251-7.
11. Bishop, N., Horman, A. and woodman, P. 2002. Mammalian class E vps proteins recognize ubiquitin and act in the removal of endosomal protein-ubiquitin conjugates. J. Cell. Biol., 157:91-101.
12. Bowers, K., Piper, S.C., Edeling, M.A., Gray, S.R., Owen, D.J., Lehner, P.J. and Luzio, J.P. 2006. Degradation of endocytosed epidermal growth factor and virally ubiquinated major histocompatibility complex class I is independent of mammalian ESCRTII. J. Biol. Chem., 281:5094-105.
13. Carpenter, G. 2003. ErbB-4: Mechanism of Action and Biology. Exp. Cell. Res., 284:66-77.
14. Carpentier, J.L., White, M.F., Orci, L. and Kahn, R.C. 1987. Direct visualization of the phosphorylated epidermal growth factor receptor during its internalization in A431 cells. J. Cell. Biol., 105:2751-62.
15. Ceresa, B.P. and Bahr, S.J. 2006. rab7 Activity Affects Epidermal Growth Factor: Epidermal Growth Factor Receptor Degradation by Regulating Endocytic Trafficking from the Late Endosome. J. Biol. Chem., 281:1099-106.
16. Chinkers, M. and Brugge, J.S. 1984. Characterization of structural domains of the human epidermal growth factor receptor obtained by partial proteolysis. J. Biol. Chem., 259:11534-42.
17. Cirri, P., Chiarugi, P., Camici, G., Manao, G., Raugei, G., Cappugi, G. and Pamponi, G. 1993. The role of Cys12, Cys17 and Arg 18 in the catalytic mechanism of low M(r) cytosolic phosphotyrosine protein phosphatase. Eur. J. Biochem., 214:647-57.
18. Citri, A., Skaria, K.B. and Yarden, Y. 2003. The Deaf and Dumb: the Biology of ErbB-2 and ErbB-3. Exp. Cell. Res., 284:54-65.
19. ClinicalTrials.gov (2007) U.S. National Institutes of Health.
20. Di Fiore, P.P., Pierce, J.H., Fleming, T.P., Hazan, R., Ullrich, A., King, C.R., Schlessinger, J. and Aaronson, S.A. 1987. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell., 51:1063-70.
21. DiGuglielmo, G.M., Baass, P.C., Ou, W.J., Posner, B.I. and Bergeron, J.J. 1994. Compartmentalization of Shc, Grb2 and mSOS, and hyperphosphorylation of raf-1 by EGF but not insulin in liver parenchyma. EMBO J., 13:4269-77.
22. Downward, J., Parker, P. and Waterfield, M.D. 1984a. Autophosphorylation sites on the epidermal growth factor receptor. Nature, 311:483-5.
23. Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., Schlessinger, J. and Waterfield, M.D. 1984b. Close similarity of epidermal growth factor receptor and v-erb-B. oncogene protein sequences. Nature, 307:521-7.
24. Doyette, A., Russell, M.R., Hopkins, C.R. and Woodman, P.G. 2005. Depletion of TSG101 forms a mammalian "Class E" compartment: a multicisternal early endosome with multiple sorting defects. J. Cell. Sci., 118:3003-17.
25. Duan, L., Miura, Y., Dimri, M., Majumder, B., Dodge, I.L., Reddi, A.L., Ghosh, A., Fernandes, N., Zhou, P., Mullane-Robsinson, K., Rao, N., Donoghue, S., Rogers, R.A., Bowtell, D., Naramura, M., Gu, H., Band, V. and Band, H. 2003. Cbl-mediated ubiquitylation is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for endocytosis. J. Biol. Chem., 278:28950-60.
26. Dunn, W.A, Connolly, T.P. and Hubbard, A.L. 1986. Receptor-mediated endocytosis of epidermal growth factor by rat hepatocytes:receptor pathway. J. Cell. Biol., 102:24-36.
27. Felder, S., Miller, K., Moehren, G., Ullrich, A., Schlessinger, J. and Hopkins, C.R. 1990. Kinase activity controls the sorting of the epidermal growth factor receptor with the multivesicular body. Cell., 61:623-34.
28. Ferguson, K.M., Berger, M.B., Medrola, J.M., Cho, H.S., Leahy, D.J. and Lemmon, M.A. 2003. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol. Cell., 11:507.
29. Fischer-Colbrie, J., Witt, A., Heinzl, H., Speiser, P., Czerwenka, K., Sevelda, P. and Zeillinger, R. 1997. EGFR. and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res., 17:613-9.
30. Flint, A.J., Tiganis, T., Barford, D. and Tonks, N.K. 1997. Development of "substrate-trapping" mutants to identify substrates for phosphatases. Proc. Natl. Acad. Sci. U.S.A, 94:1680-5.
31. French, A.R., Sudlow, G.P., Wiley, H.S. and Lauffenburger, D.A. 1994. Postendocytic Trafficking of Epidermal Growth Factor-Receptor Complexes is Mediated through Saturable and Specific Endosomal Interactions. J. Biol. Chem., 269:15749-55.
32. Futter, C.E., Collinson, L.M., Backer, J.M. and Hopkins, C.R. 2001. Human VPS34 is required for internal vesicle formation with multivesicular endosomes. J. Cell. Biol., 155:1251-64.
33. Futter, C.E., Felder, S., Schlessinger, J., Ullrich, A. and Hopkins, C. R. 1993. Annexin I is phosphorylated in the multivesicular body during the processing of the epidermal growth factor receptor. J. Cell. Biol., 120:77-83.
34. Futter, C.E., Gibson, A., Allchin, E.H., Maxwell, S., Ruddock, L.J., Odorizzi, G., Domingo, D., Trowbridge, I.S. and Hopkins, C.R. 1998. In Polarized MDCK cells basolateral vesicles arise from clathrin-g-adaptin-coated domains on endosomal tubules. J. Cell. Biol., 141:611-23.
35. Grazul-Bilska, A.T., Johnson, M.L., Bilski, J.J., Redmer, D.A., Reynolds, L.P., Abdullah, A. and Abdullah, K.M. 2003. Wound Healing: The Role of Growth Factors. Drugs Today (Barc), 39:787-800.
36. Haigler, H.T. and Carpenter, G. 1980. Production and characterization of antibody blocking epidermal growth factor:receptor interactions. Biochim. Biophys. Acta., 598:314-25.
37. Haj, F.G., Verveer, P.J., Squire, A., Neel, B.G. and Bastiaens, P.I. 2002. Imaging sites of receptor dephosphorylation by PTP1B. on the surface of the endoplasmic reticulum. Science, 295:1701-11.
38. Harari, P.M., Allen, G.W. and Bonner, J.A. 2007. Biology of interactions; antiepidermal growth factor receptor agents. J. Clin. Oncol., 25:4057-65.
39. Harris, R.C., Chung, E. and Coffey, R.J. 2003. EGF Receptor ligands. Exp. Cell. Res., 284:2-13.
40. Huang, F., Kirkpatrick, D., Jiang, X., Gygi, S. and Sorkin, A. 2006. Differential Regulation of EGF Receptor Internalization and Degradation by Multiubiquitination within the Kinase Domain. Mol. Cell., 21:737-48.
41. Huang, S.M., Bock, J.M. and Harari, P.M. 1999. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res., 59:1935-40.
42. Hurley, J.H. and Emr, S.D. 2006. The ESCRT complexes: structure and mechanism of a membrane-trafficking network. Annu. Rev. Biophys. Biomol. Struct., 35:277-98.
43. Ishitoya, J., Toriyama, M., Oguchi, N., Kitamura, K., Ohshima, M., Asano, K. and Yamamoto, T. 1989. Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck. Br. J. Cancer, 59:559.
44. Jiang, X. and Sorkin, A. 2003. Epidermal growth factor receptor internalization through clathrin-coated pits requires Cbl RING finger and proline- rich domains but not receptor polyubiquitylation. Traffic, 4:529-43.
45. Jones, M.K., Tomikawa, M., Mohajer, B. and Tarnawski, A.S. 1999. Gastrointestinal Mucosal Regeneration: Role of Growth Factors. Frontiers in Bioscience, 4:d303-9.
46. Jorissen, R.N., Walker, F., Pouliot, N., Garrett, T.P.J., Ward, C.W. and Burgess, A.W. 2003. Epidermal Growth Factor Receptor: Mechanisms of Activation and Signalling. Exp. Cell. Res., 284:31-53.
47. Katzmann, D.J., Odorizzi, G. and Emr, S.D. 2002. Receptor downregulation and multivesicular-body sorting. Nat. Rev. Mol. Cell. Biol., 3:893-905.
48. Keilhack, H., Tenev, T., Nyakatura, E., Godovac-Zimmermann, J., Nielsen, L., Seedorf, K. and Bohmer, F. 1998. Phosphotyrosine 1173 Mediates Binding of the Protein-tyrosine Phosphatase SHP-1 to the Epidermal Growth Factor Receptor and Attenuation of Receptor Signaling. J. Biol. Chem., 273:24839-246.
49. Klingler-Hoffmann, M., Fodero-Tavoletti, M.T., Mishima, K., Narita, Y., Cavenee, W.K., Furnari, F.B., Huang, H.J. and Tiganis, T. 2001. The protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor. J. Biol. Chem., 276:46313-8.
50. Korc, M. and Finman, J.E. 1989. Attenuated processing of epidermal growth factor in the face of marked degradation of transforming growth factor-alpha. J. Biol. Chem., 264:14990-9.
51. Lai, W.H., Cameron, P.H., Doherty 2nd, J.J., Posner, B.I. and Bergeron, J.J. 1989. Ligand-mediated autophosphorylation activity of the epidermal growth factor receptor during internalization. J. Cell. Biol., 109:2751-60.
52. Lammers, R., van Obberghen, E., Ballotti, R., Schlessinger, J. and Ullrich, A. 1990. Transphosphorylation as a possible mechanism for insulin and epidermal growth factor receptor activation. J. Biol. Chem., 265:16886-90.
53. Langelier, C., von Schwedler, U.K., Fisher, R.D., DeDomenico, I., White, P.L., Hill, C.P., Kaplan, J., Ward, D. and Sundquist, W.I. 2006. Human ESCRT-II complex and its role in human immunodeficiency virus type 1 release. J. Virol., 80:9465-80.
54. Lenferink, A.E.G., Pinkas-Kramarski, R., van de Poll, M.L.M., van Vugt, M.J.H., Klapper, L.N., Tzahar, E., Waterman, H., Sela, M., van Zoelan, E.J.J. and Yarden, Y. 1998. Differential endocytic routing of homo- and hetero-dimeric ErbB. tyrosine kinases confers signaling superiority to receptor heterodimers. The EMBO J., 17:3385-97.
55. Levkowitz, G., Waterman, H., Ettenberg, S.A., Katz, M., Tsygankov, A.Y., Alroy, I., Lavi, S., Iwai, K., Reiss, Y., Ciechanover, A., Lipkowitz, S. and Yarden, Y. 1999. Ubiquitin ligase activity and tyrosine phophorylation underlie suppression of growth factor signaling by c- Cbl/Sli-1. Mol. Cell., 4:1029-40.
56. Li, L. and Cohen, S.N. 1996. Tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell., 85:319-29.
57. Liao, H.J. and Carpenter, G. 2007. Role of the Sec61 translocon in EGF receptor trafficking to the nucleus and gene expression. Mol. Biol. Cell., 18:1064-72.
58. Libermann, T.A., Nusbaum, H.R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M.D., Ullrich, A. and Schlessinger, J. 1985. Amplication, enhanced expression and possible rearrangement of EGFR. gene in primary human brian tumours of glial origin. Nature, 313:144-7.
59. Lu, Q., Hope, L.W., Brasch, M., Reinhard, C. and Cohen, S.N. 2003. TSG101 interaction with HRS mediates endosomal trafficking and receptor down-regulation. Proc. Natl. Acad. Sci. U.S.A, 100:7626-31.
60. Luetteke, N.C., Qiu, T.H., Fenton, S.E., Troyer, K.L., Riedel, R.F., Chang, A. and Lee, D.C. 1999. Targeted inactivation of the EGF and Amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland developement. Development, 126:2739-50.
61. Lund, K.A., Opresko, L.K., Starbuck, C., Walsh, B.J. and Wiley, H.S. 1990. Quantitative analysis of the endocytic system involved in hormone-induced receptor internalization. J. Biol. Chem., 265:15713-23.
62. Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., Louis, D.N., Christiani, D.C., Settleman, J. and Haber, D.A. 2004. Activating mutations in the epidermal growth factor receptor underlysing responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 350:2129-39.
63. Magne, N., Pivot, X., Bensadoun, R.J., Guardiola, E., Poissonnet, G., Dassonville, O., Francoual, M., Formento, J.L., Demard, F., Schneider, M. and Milano, G. 2001. The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy. Eur. J. Cancer, 37:2169-77.
64. Malerod, L., Stuffers, S., Brech, A. and Stenmark, H. 2007. Vps22/EAP30 in ESCRT-II Mediates Endosomal sorting of growth factor and chemokine receptors destined for lysosomal degradation Traffic, in press.
65. Masui, H., Castro, L. and Mendelsohn, J. 1993. Consumption of EGF by A431 cells: evidence for receptor recycling. J. Cell. Biol., 120:85-93.
66. Melisi, D., Troiani, T., Damiano, V., Tortora, G. and Ciardiello, F. 2004. Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. Endocr. Relat. Cancer, 11:51-68.
67. Merlino, G.T., Xu, Y.H., Ishii, S., Clark, A.J., Semba, K., Toyoshima, K., Yamamoto, T. and Pastan, I. 1984. Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. Science, 224:417-9.
68. Miettinen, P.J., Berger, J.E., Meneses, J., Phung, Y., Pedersen, R.A., Werb, Z. and Derynck, R. 1995. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature, 376:337-41.
69. Miller, K., Beardmore, J., Kanety, H., Schlessinger, J. and Hopkins, C.R. 1986. Localization of the epidermal growth factor (EGF) receptor within the endosome of EGF-stimulated epidermoid carcinoma (A431) cells. J. Cell. Biol., 102:500-9.
70. Miller, W.E., Earp, H.S. and Raab-Traub, N. 1995. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J. Virol., 69:4390-8.
71. Mizuno, E., Iura, T., Mukai, A., Yoshimori, T., Kitamura, N. and Komada, M. 2005. Regulation of epidermal growth factor receptor down-regulation by UBPY-mediated deubiquitination at endosomes. Mol. Biol. Cell., 16:5163-74.
72. Morgillo, F., Bareschino, M.A., Bianco, R., Tortora, G. and Ciardiello, F. 2007. Primary and acquired resistance to anti-EGFR. targeted drugs in cancer therapy. Differentiation, in press.
73. Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S. and Bardelli, A. 2005. Gene copy number for epidermal growth factor receptor (EGFR.) and clinical response to antiEGFR. treatment in colorectal cancer: a cohort study. Lancet Oncol., 6:279-86.
74. Moy, B., Kirkpatrick, P., Kar, S. and Goss, P. 2007. Lapatinib. Nat. Rev. Drug Discov. 6:431-2.
75. Newby, J.S., Johnston, S.R., Smith, I.E. and Dowsett, M. 1997. Expression of epidermal growth factor receptor and c-erbB.2 during the development of tamoxifen resistance in human breast cancer. Clin. Cancer Res., 3:1643-51.
76. O'Grady, M., Raha, D., Hanson, B.J., Bunting, M. and Hanson, G.T. 2005. Combining RNA interference and kinase inhibitors against cell signalling components involved in cancer. BMC Cancer, 5.
77. Oksvold, M.P., Skarpen, E., Wierod, L., Paulsen, R.E. and Huitfeldt, H.S. 2001. Re-localization of activated EGF receptor and its signal transducers to multivesicular compartments downstream of early endosomes in response to EGF. Eur. J. Cell. Biol., 80:285-94.
78. Olabisi, O.O., Mahon, G.M., Kostenko, E.V., Liu, Z., Ozer, H.L. and Whitehead, I.P. 2006. Bcr interacts with components of the endosomal sorting complex required for transport-I and is required for epidermal growth factor receptor turnover. Cancer Res., 66:6250-7.
79. Raymond, C.K., Howald-Stevenson, I., Vater, C.A. and Stevens, T.H. 1992. Morphological classification of the yeast vacuolar protein sorting mutants: evidence for a prevacuolar compartment in E vps mutants. Mol. Biol. Cell., 3:1389-402.
80. Razi, M. and Futter, C.E. 2006. Distinct roles for Tsg101 and Hrs in multivesicular body formation and inward vesiculation. Mol. Biol. Cell., 17:3469-83.
81. Rocha-Lima, C.M., Soares, H.P., Raez, L.E. and Singal, R. 2007. EGFR. Targeting of Solid tumors. Cancer Control, 14:295-304.
82. Row, P.E., Prior, I.A., McCullough, J., Clague, M.J. and Urbe, S. 2006. The ubiquitin isopeptidase UBPY regulates endosomal ubiquitin dynamics and is essential for receptor down-regulation. J. Biol. Chem., 281:12618-24.
83. Sachse, M., Strous, G.J. and Klumperman, J. 2004. ATPase-deficient hVPS4 impairs formation of internal endosomal vesicles and stabilizes bilayered clathrin coats on endosomal vacuoles. J. Cell. Sci., 117:1699-1708.
84. Sebastian, S., Settleman, J., Reshkin, S.J., Azzariti, A., Bellizzi, A. and Paradiso, A. 2006. The complexity of targeting EGFR. signalling in cancer: from expression to turnover. Biochim Biophys. Acta., 1766:120-39.
85. Sibilia, M. and Wagner, E.F. 1995. Strain-dependent epithelial defects in mice lacking the EGFR. Science, 269:234-8.
86. Sorkin, A. and von Zastrow, M. 2002. Signal Transduction and Endocytosis: Close Encounters of Many Kinds. Nat. Cell. Biol. Rev., 3:600-14.
87. Suarez Pestana, E., Tenev, T., Gross, S., Stoyanov, B., Ogata, M. and Bohmer, F.D. 1999. The transmembrane protein tyrosine phosphatase RPTPsigma modulates signaling of the epidermal growth factor receptor in A431 cells. Oncogene, 18:4069-79.
88. Tiganis, T., Bennet, A.M., Ravicharndran, K.S. and Tonks, N.K. 1998. Epidermal Growth Factor receptor and the adaptor protein p52Shc are specific substrates of T-cell protein tyrosine phosphatase. Mol. Cell. Biol., 18:1622-34.
89. Tiganis, T., Kemp, B.E. and Tonks, N.K. 1999. The protein-tyrosine phosphatase TCPTP regulates epidermal growth factor receptor-mediated and phosphatidylinositol 3-kinase-dependent signaling. J. Biol. Chem., 274:27768-75.
90. Tomic, S., Greiser, U., Lammers, R., Kharitonenkov, A., Imyanitov, E., Ullrich, A. and Bohmer, F.D. 1995. Assoication of SH2 domain protein tyrosine phosphatases with the epidermal growth factor receptor in human tumor cells. Phasphatidic acid activates receptor dephosphorylation by PTP1C. J. Biol. Chem., 270:21277-84.
91. Tonks, N.K. 2006. Protein tyrosine phosphatases: from genes, to function, to disease. Nat. Rev. Mol. Cell. Biol., 7:833-46.
92. Tonks, N.K., Diltz, C.D. and Fischer, E.H. 1988. Purification of the major protein-tyrosine-phosphatases of human placenta. J. Bio Chem., 263:6722-30.
93. Tonks, N.K. and Neel, B.G. 2001. Combinatorial control of the specificity of protein tyrosine phosphatases. Curr. Opin. Cell. Biol., 13:182-95.
94. Tsutsumi, O., Kubota, Y. and Oka, T. 1987. Effect of sialoadenectomy, treatment with epidermal growth factor (EGF) antiserum and the replacement of EGF on the epidermis in mice. J. Endocrinol., 113:193-7.
95. Ullrich, A., Coussens, L., Hayflick, J.S., Dull, T.J., Gray, A., Tam, A.W., Lee, J., Yarden, Y., Libermann, T.A. and Schlessinger, J. 1984. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature, 309:418-25.
96. Urbe, S., Sachse, M., Row, P.E., Presisinger, C., Barr, F.A., Strous, G., Klumperman, J. and Clague, M.J. 2003. The UIM domain of Hrs couples receptor sorting to vesicle formation. J. Cell. Sci., 116:4169-79.
97. Velu, T.J., Beguinot, L., Vass, W.C., Willingham, M.C., Merlino, G.T., Pastan, I. and Lowry, D.R. 1987. Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science, 238:1408-10.
98. Vieira, A.V., Lamaze, C. and Schmid, S.L. 1996. Control of EGF Receptor Signaling by Clathrin-Mediated Endocytosis. Science, 274:2086-9.
99. Ward, D.M., Vaughn, M.B., Shiflett, S.L., White, P.L., Pollock, A.L., Hill, J., Schnegelberger, R., Sundquist, W.I. and Kaplan, J. 2005. The role of LIP5 and CHMP5 in multivesicular body formation and HIV-1 budding in mammalian cells. J. Biol. Chem., 280:10548-55.
100. Wells, A., Welsh, J.B., Lazar, C.S., Wiley, H.S., Gill, G.N. and Rosenfeld, M.G. 1990. Ligand-Induced Transformation by a Noninternalizing Epidermal Growth Factor Receptor. Science, 247:962-4.
101. White, I.J., Bailey, L.M., Aghakhani, M.R., Moss, S.E. and Futter, C.E. 2006. EGF stimulates annexin 1-dependent inward vesiculation in a multivesicular endosome subpopulation. EMBO J., 25:1-12.
102. Wiley, H.S. 2003. Trafficking of the ErbB. receptors and its influence on signaling. Exp. Cell. Res., 284:78-88.
103. Xu, Y., Tan, L.J., Grachtchouk, V., Voorhees, J.J. and Fisher, G.J. 2005. Receptor-type protein-tyrosine phosphatase-kappa regulates epidermal growth factor receptor function. J. Biol. Chem., 280:42694-700.
104. Yamamoto, T., Kamata, N., Kawano, H., Shimizu, S., Kuroki, T., Toyoshima, K., Rikimaru, K., Nomura, N., Ishizaki, R. and Pastan, I. 1986. High incidence of amplification of the epidermal growth factor receptor gene in human squamous carcinoma cell lines. Cancer Res., 46:414-6.
105. Yamazaki, H., Kijima, H., Ohnishi, Y., Abe, Y., Oshika, Y., Tsuchida, T., Tokunaga, T., Tsugu, A., Ueyama, Y., Tamaoki, N. and Nakamura, M. 1998. Inhibition of tumor growth by ribozyme-mediate suppression of aberrant epidermal growth factor receptor gene expression. J. Natl. Cancer Inst., 90:581-7.
106. Yan, Q., Hunt, P.R., Freliin, L., Vida, T.A., Pevsner, J. and Bean, A. J. 2005. mVps24p functions in EGF receptor sorting/trafficking from the early endosome. Exp. Cell. Res., 304:265-73.
107. Yano, S., Kondo, K., Yamaguchi, M., Richmond, G., Hutchison, M., Wakeling, A., Averbuch, S. and Wadsworth, P. 2003. Distribution and function of EGFR. in human tissue and the effect of EGFR. tyrosine kinase inhibition. Anticancer Res., 23:3639-50.
108. Yarden, Y. and Sliwkowski, M.X. 2001. Untangling the ErbB. Signalling Network. Nat. Rev. Mol. Cell. Biol., 2:127-37.
109. Yoon, C.H., Lee, J., Jongeward, G.D. and Sternberg, P.W. 1995. Similarity of sli-1, a regulator of vulval development in C. elegans, to the mammalian proto-oncogene c-cbl. Science, 269:1102-5.
110. Zandi, R., Larsen, A.B., Andersen, P., Stockhausen, M.T. and Poulsen, H.S. 2007. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell. Signal, 19:2013-23.
111. Zhang, Z.Y. and VanEtten, R.L. 1991. Pre-steady-state and steady-state kinetic analysis of the low molecular weight phosphotyrosyl protein phosphatase from bovine heart. J. Biol. Chem., 266:1516-25.
112. Zhu, Z. 2007. Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives. Acta. Pharmacol. Sin, 28:1476-93.